Table 3.

Multivariate analysis for factors associated with a local-regional recurrence in breast cancer patients undergoing surgery first and in patients receiving neoadjuvant chemotherapy

Surgery First					Neoadjuvant Chemotherapy
Factor	Hazard Ratio	Standard Error	P value	95% Confidence Interval	Factor	Hazard Ratio	Standard Error	P value	95% Confidence Interval
Clinical stage III	4.13	2.43	o.016	1.3-13.11	Clinical stage III	1.97	.56	0.017	1.13-3.44
Nuclear grade 3	1.69	.37	0.015	1.11-2.60	Nuclear grade 3	3.39	1.56	0.008	1.37-8.36
ER negative	2.18	.58	0.003	1.30-3.67	ER negative	2.00	.63	0.027	1.08-3.69
Close/positive margins	2.56	.86	0.005	1.33-4.94	Close/positive margins	3.04	1.47	0.022	1.17-7.86
ER positive/no endocrine therapy	2.88	.76	<0.001	1.72-4.84	LVI present	2.30	.71	0.007	1.26-4.20
Multifocal Disease	1.89	.61	0.048	1.01-3.55	Path stage ≥ I	2.73	1.21	0.024	1.14-6.52
Age < 50	2.18	.45	<.001	1.45-3.27

Abbreviations: ER, estrogen receptor; LVI, lymphovascular invasion